Who is Liraglutide for:

Liraglutide is intended for adults aged 18 to 74 who meet specific criteria:

1. Previous weight management efforts
   For those who have not achieved meaningful weight loss through supervised diet, behaviour changes, and increased physical activity.
2. Body Mass Index (BMI) requirements *
   • BMI of 30 kg/m² or higher or
   • BMI of 27 kg/m² or higher with at least one weight-related health condition, such as:
     • High blood pressure (hypertension)
     • High cholesterol (dyslipidaemia)
     • Obstructive sleep apnoea
     • Type 2 diabetes

Consultation process

Our service does not include a prescription. Instead, your treatment will be supplied under a legal framework called Patient Group Direction (PGD), and the process will follow these steps:

1. Complete a health questionnaire:

Provide detailed information about your health, medical history, and previous weight management attempts.

2. Pharmacist assessment:

Our pharmacist will review your responses and will reach out via phone or video call to confirm your suitability for Liraglutide.

3. Private consultation:

All consultations are private and confidential. This gives you the opportunity to ask questions and ensure Liraglutide is the right choice for your needs.

4. All-inclusive pricing:

The price you pay includes the consultation fee, with no hidden costs.

5. Identity verification:

You'll need to provide identification during the consultation to confirm that you are the intended user. This is required only during your first order.

6. Photographic evidence request:

You’ll be asked to submit photographic evidence of your weight, height, and relevant medical history to ensure safe and accurate consultation.

Dosage

Liraglutide follows a gradual titration schedule to help your body adjust and minimise potential side effects as you increase to an effective maintenance dose. Starting with the lowest dose and gradually increasing it every week is advised. Please select the dosage as recommended in your personalised treatment plan. If you’re uncertain about the right dose, please contact our pharmacist at (pharmacy@medino.com) before ordering.

Purchasing this medication does not guarantee its supply. The decision if this medication is right for you will be made together with the pharmacist during your consultation, and ultimately the decision to supply the medication is with the pharmacist. Any orders found not suitable will be refunded.

For individuals with a BMI over 50, we strongly recommend consulting with a doctor or specialist for a comprehensive treatment plan.

Liraglutide is the active ingredient in the brand-name medication Saxenda. This is the generic version.

Patient information leaflet

Active ingredient: liraglutide. 1 ml solution for injection contains 6 mg liraglutide. One pre-filled pen contains 18 mg liraglutide.

Other ingredients: sodium citrate dihydrate, propylene glycol, phenol, water for injection, hydrochloric acid and/or sodium hydroxide solution.

Patient information leaflet

The starting dose is 0.6 mg once daily.
The dose should be increased to 3.0 mg once daily in increments of 0.6 mg with at least one-week intervals to improve gastrointestinal tolerability (see Table).
If escalation to the next dose step is not tolerated for two consecutive weeks, consider discontinuing treatment.
Daily doses higher than 3.0 mg are not recommended.

Dose Escalation Schedule (4 weeks)

Liraglutide should not be used in people allergic to its ingredients or in those with severe heart failure (NYHA IV).

It is not recommended for:

• patients aged 75+,
• people with severe liver or kidney problems
• those using other weight-loss drugs.

Use cautiously in people with mild to moderate liver issues, thyroid disease, or gastrointestinal disorders such as gastroparesis. It may cause nausea, vomiting, diarrhoea, gallstones, or pancreatitis. Stop treatment if pancreatitis occurs.

Monitor for increased heart rate and dehydration. Liraglutide can interact with insulin, sulfonylureas, warfarin, digoxin, lisinopril, and oral contraceptives, though most effects are minor.

Avoid use during pregnancy and breastfeeding. It may slightly affect fertility in animals.

May cause dizziness during the first months of treatment; caution is advised when driving or operating machinery.

* More frequent when used with insulin or sulfonylurea
** Usually transient
*** Reported during clinical trials
**** Due to mechanism of action
† Reported post-marketing